Vanishing bile duct syndrome (VBDS) is a heterogeneous group of biliary diseases characterized by progressive loss of intrahepatic bile ducts or cholestasis. 1 Diagnosis is confirmed by liver biopsy showing loss of interlobular bile ducts in .50% of sampled portal tracts. 2 Adult patients typically have concurrent liver diseases. [1] [2] [3] [4] [5] [6] Pediatric case reports associate the development of VBDS with Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN; see Table 1 ). These cases led to the hypothesis that VBDS can be caused by the same hyperimmune response that causes SJS/TEN. 1, 3, 4, 7 Because of the limited cases, therapeutic interventions vary. Refractory cases have used immunosuppression, most commonly the calcineurin inhibitor tacrolimus, with mixed results. 1, 3, 4 With increased knowledge of the pathophysiology, it has been suggested that tumor necrosis factor-a (TNF-a) inhibitors may represent an alternative therapy. 4 Our patient, a 6-year-old boy, represents the first reported use of a TNF-a inhibitor and plasmapheresis for treatment of VBDS associated with TEN. We also summarized the presentation, management, and response to other therapies of patients with VBDS secondary to TEN.
CASE REPORT
A 6-year-old Puerto Rican/African American male, withpast medicalhistoryofasthma, presented to an outside hospital 3 weeks before presentation at our institution with chief complaints of fever, rhinorrhea, and cough. He was diagnosed with pneumonia and discharged from the hospital with cefdinir. He returned a week later with no improvement, was admitted, and received intravenous ceftriaxone and methylprednisolone. Admission laboratories showed total bilirubin of 2.7 mg/dL, aspartate aminotransferase (AST) 233 U/L, alanine aminotransferase (ALT) 127 U/L, alkaline phosphatase (AP) 631 U/L, g glutamyl transferase (GGT) 608 U/L, and lipase 1707 U/L.
Subsequently he developed an erythematous macular rash, conjunctivitis, chapped lips, sterile pyuria, and respiratory distress and received intravenous immunoglobulin and aspirin for presumed Kawasaki disease. His respiratory status worsened, and he was admitted to the ICU 10 days before transfer to our institution.
In the ICU, the rash evolved to scattered groupings of vesicles involving the oral mucosa, prompting a skin biopsy, which showed interface inflammation with scant lymphocytic infiltrate and epithelial cell necrosis, diagnostic of TEN. AST increased to 442 U/L, ALT to 245 U/L, GGT to 829 U/L, and total bilirubin to 7.3 mg/dL. International normalized ratio (INR) was 1.94, and ammonia was 115 umol/L. Mycoplasma immunoglobulin M levels were elevated, and azithromycin was started.
He was then referred to a liver transplant center for evaluation 7 days before transfer to our hospital. Spironolactone, lactulose, rifampin, ursodiol, and vitamin Kwere added to his medications. His transaminitis stabilized (AST 366 U/L, ALT 295 U/L), and INR normalized; however, his total bilirubin rose to 16.4 mg/dL (direct 12.2 mg/dL). Hepatitis panel, Epstein-Barr virus, cytomegalovirus, HIV, herpes simplex virus 1/2 titers were all negative. Four days before transfer to our hospital, he was switched from azithromycin to levofloxacin to minimize hepatic toxicity, and vancomycin and cefepime were begun due to rising white blood cell count. No pathogens were cultured. He had worsening blisters and skin sloughing and was transferred for wound care.
Upon admission, he was afebrile and normotensive. Physical examination revealed a sedated boy with sloughing skin on his ears, trunk, bilateral arms, and legs. Eschar was noted on his eyelids and lips. Abdominal examination showed hepatomegaly, with the liver edge 2 cm below the costal margin. The remainder of his examination was unremarkable.
Laboratory evaluation showed a normal complete blood count and basic metabolic panel. Erythrocyte sedimentation rate was 78 mm/hour, and C-reactive protein was 6.2mg/dL. A liver function panel showed a total protein of 5.2 g/dL, albumin of 2.7 g/dL, total bilirubin of 21.2 Aminotransferases by day of illness.
was changed to phenobarbital. His condition worsened, requiring inotropic support and multiple blood transfusions. On hospital day 32, he suffered an acute decompensation requiring resuscitative measures, with stabilization on dopamine and norepinephrine drips. Despite interventions, he died on hospital day 51.
DISCUSSION
VBDS is an uncommon diagnosis, rare in children, with scattered cases associated with SJS/TEN. Previous case reports in which patients had both diagnoses speculated that a hyper-immune response damages the biliary system, leading to VBDS, 1,3,4,7 which we believe occurred in our patient. It is possible that an infection or medication triggered the process.
VBDS can progress despite discontinuation of offending medications. Conversely, transaminase and bilirubin levels can improve despite persistent loss of bile ducts. 2 We felt that our patient' s liver status was stabilizing/improving, so were hesitant to intervene aggressively for his liver disease. The decision to trial medications was based on his lifethreatening multiorgan failure.
Because of limited knowledge of the pathogenesis of VBDS, therapies have been chosen to blunt the immune response. Tacrolimus has had mixed results. 1, 3, 4 We concluded that the risk/ benefit ratio for tacrolimus in our patient was too high, given his kidney and lung injury. Intravenous immunoglobulin has also been used in adults that developed VBDS secondary to graftversus-host disease and for a patient with VBDS secondary to TEN but was unable to prevent progression to liver transplant in those cases. 8, 9 Literature review suggested the use of TNF-a blockade. 4 Okan et al did not use TNF-a blockade but hypothesized that it could be effective because case reports showed rapid resolution of skin and mucosal damage in patients with SJS/TEN after administration of infliximab, 10, 11 together with the theory of a common immunologic mechanism. [1] [2] [3] [4] [5] [6] [7] [12] [13] [14] Infliximab has been reported to increase the incidence of infections, but the majority of reports have been upper respiratory tract illnesses, ,2% of which were pneumonia. 15 We chose infliximab for our patient because of its more favorable side effect profile.
Our patient also received plasmapheresis because of the shared immunologic pathway hypothesis. Reau et al noted that the cell death receptor CD95 (Fas) and its ligand (Fas-L) have been implicated in bile duct injury. 2 Similarly, elevated levels of Fas-L have been found in TEN patients, 16 and a case series showed resolution of the TEN mucosal damage once plasmapheresis was initiated, correlating with removal of Fas-L from the serum. 17 Its use in patients with isolated VBDS is limited. A case report showed minimal improvement after plasma exchange. 18 Given our patient' s critical condition, this therapy was used to attempt to blunt systemic inflammation.
We report another case of VBDS associated with TEN, but the first using both a TNF-a blocker and plasmapheresis. Because this is an uncommon condition, there is no standardized therapeutic approach. Despite our patient' s death, TNF-a blockade and/or plasmapheresis may still offer therapeutic alternatives for VBDS, although we acknowledge that follow-up is short, his condition was grave, and confounding therapies were used, making it difficult to know which, if any, were effective. His bilirubin levels decreased and stabilized until the days before his demise, with liver pathology from autopsy confirming VBDS. The long-term ability of infliximab to blunt further destruction and allow for biliary regeneration is undefined compared with tacrolimus because previous cases using calcineurin inhibitors followed their patients for at least 6 months from time of injury. Those cases showed mixed results, with 2 patients showing clinical resolution and 1 patient requiring liver transplant (see Table 1 ). 1, 3, 4, 7 Longer follow-up will be required to evaluate infliximab' s efficacy. Our case also supports choleresis for VBDS because our patient' s bilirubin levels declined once ursodiol was started.
AlthoughVBDSisararesequelaeofSJS/TEN, it should remain on the clinician' s differential for conjugated hyperbilirubinemia.
More clinical studies are needed to determine the optimal therapy for both disorders.
